Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071250 | 1.00 | GAA (0.76) | GAANPC1RAB9APKMSMN1; SMN2 | |
| Bromide SCHEMBL11500766 | 0.98 | GAA (0.73) | GAANPC1RAB9APKMSMN1; SMN2 | |
| Trifluoromethylbenzene SCHEMBL10520526 | 0.87 | GAA (0.58) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL6245092 | 0.86 | GAA (1.00) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL2562391 | 0.86 | GAA (0.71) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL9689348 | 0.84 | GAA (0.79) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL4491035 | 0.83 | GAA (0.79) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL7006640 | 0.83 | GAA (0.79) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL23976543 | 0.83 | GAA (0.67) | GAANPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL10790442 | 0.83 | HDAC3 (0.70) | GAANPC1RAB9APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634975-B1 | 17-OXIMES OF 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES | ORGANON R&D FINLAND LTD (FI) | 2024-02-28 | — | — | EP | claimed |
| EP-3941906-B1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-110945007-B | 15 beta- [ 3-propionylamino ] -substituted estra-1, 3,5 (10) -trien-17-one compounds and 17-oximes thereof for inhibiting 17 beta-hydroxysteroid dehydrogenases | 佛恩多制药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-3634975-A2 | 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONE COMPOUNDS AND THEIR 17-OXIMES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES | Forendo Pharma Ltd (FI) | 2020-04-15 | — | — | EP | claimed |
| WO-2018224736-A2 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | FORENDO PHARMA LTD (FI) | 2018-12-13 | — | — | WO | claimed |
| CN-104592006-B | A kind of synthetic method of phenylpropionic acid compound | 郑州大学 | 2016-10-26 | — | — | CN | claimed |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1915363-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018469-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-09 | — | — | US | disclosed |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | ATOM THERAPEUTICS CO., LTD (CN) | 2025-06-17 | — | — | US | disclosed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-3915984-B1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-ALPHA]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-12129233-B2 | Water-soluble salts of cannabinoids, preparation and uses thereof | Aurora Fine Chemicals LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-6110729-A | TREATING RACEMIC COMPOUND WITH A STEREOSELECTIVE HYDROLASE AND ISOLATING PRODUCT; FOR CELLULAR POTASSIUM CHANNEL OPENERS USEFUL IN TREATMENT OF URINARY INCONTEINENCE, HYPERTENSION, ASTHMA, PERIPHERAL VASCULAR DISEASE, AND ANGINA | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-0904400-A2 | ENZYMATIC PROCESS FOR STEREOSELECTIVE PREPARATION OF THERAPEUTIC AMIDES | AstraZeneca AB (SE) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997038124-A2 | ENZYMATIC PROCESS FOR STEREOSELECTIVE PREPARATION OF THERAPEUTIC AMIDES | ZENECA LIMITED (GB) | 1997-10-16 | — | — | WO | disclosed |
| US-5453512-A | Bromination of acylaminopyridine with 2-acylaminopyridinium hydorbromide | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
| US-5290943-A | Halogenation of pyridine compound | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0530524-A1 | Method of producing 2-amino-3-nitro-5-halogenopyridine | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | GAA 168/4885NPC1 982/4885RAB9A 1538/4885 |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | CYP1B1, CYP8B1, HAO2 | GAA 2919/4885NPC1 4489/4885RAB9A 2870/4885 |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | GAA 3040/4885NPC1 2039/4885RAB9A 1964/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | GAA 939/4885NPC1 1788/4885RAB9A 716/4885 |
| US-12129233-B2 | Water-soluble salts of cannabinoids, preparation and uses thereof | CNR1, CNR2, FAAH | GAA 3628/4885NPC1 306/4885RAB9A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.